William Blair analyst Tim Lugo initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating.
CORRECTION: Lovesac Co Expects Q1 Net Sales of $126M-$132M Vs $147.53M Est and EPS of $(0.84)-$(1.03) Vs $(0.15) Est, FY25 Net Sales of $700M-$770M Vs $765.38M Est and EPS of $1.06-$1.59 Vs $2.15 Est
The Company expects the following for the full year of fiscal 2025:
Net sales in the range of $700 million to $770 million.
Adjusted EBITDA1 in the range of $46 million to $60 million.
Net income in the range of $18
